← Back to Screener
NanoViricides Inc. (NNVC)
Price$1.28
Favorite Metrics
Price vs S&P 500 (26W)-12.77%
Price vs S&P 500 (4W)22.43%
Market Capitalization$29.59M
All Metrics
Book Value / Share (Quarterly)$0.51
P/TBV (Annual)3.12x
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)9.34%
EPS (TTM)$-0.48
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-0.48
EPS (Annual)$-0.74
ROI (Annual)-57.77%
Cash / Share (Quarterly)$0.24
ROA (Last FY)-50.83%
EBITD / Share (TTM)$-0.45
ROE (5Y Avg)-52.73%
Cash Flow / Share (Annual)$-0.51
P/B Ratio2.67x
P/B Ratio (Quarterly)2.20x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-109.25x
ROA (TTM)-84.28%
EPS Incl Extra (Annual)$-0.74
Current Ratio (Annual)1.28x
Quick Ratio (Quarterly)4.31x
3-Month Avg Trading Volume0.27M
52-Week Price Return-3.76%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.50
52-Week High$2.23
EPS Excl Extra (Annual)$-0.74
CapEx CAGR (5Y)41.62%
Tangible BV CAGR (5Y)-19.57%
26-Week Price Return-5.88%
Quick Ratio (Annual)1.19x
13-Week Price Return13.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.43x
Enterprise Value$24.435
Book Value / Share Growth (5Y)-28.34%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.09
3-Month Return Std Dev86.19%
Net Income / Employee (TTM)$-1
ROE (Last FY)-57.77%
Net Interest Coverage (Annual)-1.58x
EPS Basic Excl Extra (Annual)$-0.74
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.48
ROI (TTM)-96.18%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.43
Price vs S&P 500 (52W)-38.39%
Year-to-Date Return13.27%
5-Day Price Return23.08%
EPS Normalized (Annual)$-0.74
ROA (5Y Avg)-46.67%
Month-to-Date Return40.34%
Cash Flow / Share (TTM)$-0.71
EBITD / Share (Annual)$-0.71
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-52.06%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.48
P/TBV (Quarterly)2.27x
P/B Ratio (Annual)2.99x
Book Value / Share (Annual)$0.45
Price vs S&P 500 (13W)10.89%
Beta1.61x
Revenue / Share (TTM)$0.00
ROE (TTM)-96.18%
52-Week Low$0.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NNVCNanoViricides Inc. | — | — | — | — | $1.28 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nanoviricides is a nano-biopharmaceutical company developing antiviral therapeutics for life-threatening viral infections using proprietary nanomedicine technologies. The company builds its pipeline through internal research programs and strategic in-licensing partnerships. This platform-based approach targets areas of significant unmet need in viral disease treatment.